AlirocumabIntervention2 papersHumans1LatestNov 2025: 0Dec 2025: 0Jan 2026: 0Feb 2026: 0Mar 2026: 0Apr 2026: 0May 2026: 0Jun 2026: 0Jul 2026: 0Aug 2026: 0Sep 2026: 2Oct 2026: 02AtherosclerosisHumans·30 SepLipoprotein(a) reduction with PCSK9-targeting pharmacotherapy: A prospective real-world registry studyThe Annals of PharmacotherapyReview·26 SepLerodalcibep-liga as an Injectable Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9)-Targeted Therapy for Patients With Hypercholesterolemia
AtherosclerosisHumans·30 SepLipoprotein(a) reduction with PCSK9-targeting pharmacotherapy: A prospective real-world registry study
The Annals of PharmacotherapyReview·26 SepLerodalcibep-liga as an Injectable Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9)-Targeted Therapy for Patients With Hypercholesterolemia